Retrospective analyses have revealed that a sequential increase in p14/ARF expression from normal to atypical ductal hyperplasia to ductal carcinoma in situ, with p14/ARF expression stabilizing as the tumor progresses. This evidence concerns the gene CDKN2A and ductal breast carcinoma in situ.